Innate Pharma’s activity is to discover, characterize and develop drug-candidates.
Its skills go from sourcing and validation of targets to the clinical development through all the steps required to process the drug-candidate. At each step, the Company has built a partnership network with academic institutions, cancer centers or industrial partners.
Identification / licensing of innovative targets
The starting point for our research is mainly through the identification of innovative targets and the acquisition of patent rights to targets, active molecules or therapeutic methods, mainly from academic research.
To acquire commercial rights from research institutions, Innate Pharma must maintain a high level of expertise and recognition in the scientific community. Our specialization plays an important role and our visibility is ensured, notably thanks to the involvement by our Company’s founding scientists, who have made very significant contributions to progress in the field.
Validation of the therapeutic concept
Validation requires in vitro and in vivo efficacy models, the ability to evaluate pharmacodynamic activity in the relevant animal models and expertise in clinical biology for the design and realization of retrospective studies in cooperation with hospital staff. These different approaches can then be implemented all along the development.
Drug candidate generation
The next step is to generate an optimized drug-candidate from a model molecule. For antibodies, this model can be murine antibody, which is not suitable for human use. To generate a recombinant humanized antibody we have implemented a high throughput platform for antibody generation and humanization.
Drug candidate development
Our specialization in immunopharmacology and clinical immunology provides us with special expertise in the mechanisms of action common to all of our drug-candidate, an important asset for this part of development. We possess specific expertise in setting up preclinical toxicology and pharmacology in animal models (cell culture laboratories, generation of non-standard animal models, flow cytometry, etc.). This gives us a competitive advantage beyond our main field of expertise.
Approximately half of our research and development staff is specialized in immunology. The other half is specialized in the various branches involved in development: chemistry and analytical chemistry, protein chemistry, bio analytical and pharmacokinetic methods and pharmacotoxicology.
As at end-2016, the Company is or has been sponsor of several Phase I and Phase II clinical trials. It is today sponsor of the double-blind placebo randomized Phase II trial of lirilumab, within the frame of its partnership with Bristol-Myers Squibb. See Company's pipeline and ongoing clinical trials.